FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2945598045> ?p ?o ?g. }

• W2945598045 endingPage "195" @default.
• W2945598045 startingPage "184" @default.
• W2945598045 abstract "Ibrutinib (IBR), an irreversible Bruton’s tyrosine kinase (BTK) inhibitor, is expected to be a potent therapeutic modality, given that BTK is overexpressed in tumor-associated macrophages (TAMs) and participates in promoting tumor progression, angiogenesis, and immunosuppression. However, rapid clearance in vivo and low tumor accumulation have rendered effective uptake of IBR by TAMs challenge. Herein, we designed and synthesized a sialic acid (SA)–stearic acid conjugate modified on the surface of nanocomplexes to encapsulate IBR (SA/IBR/EPG) for targeted immunotherapy. Amphiphilic egg phosphatidylglycerol (EPG) structure and strong IBR-EPG interactions render these nanocomplexes high IBR loading capacity, prolonged blood circulation, and optimal particle sizes (∼30 nm), which can effectively deliver IBR to the tumor, followed by subsequent internalization of IBR by TAMs through SA-mediated active targeting. In vitro and in vivo tests showed that the prepared SA/IBR/EPG nanocomplexes could preferentially accumulate in TAMs and exert potent antitumor activity. Immunofluorescence staining analysis further confirmed that SA/IBR/EPG remarkably inhibited angiogenesis and tumorigenic cytokines released by TAM and eventually suppressed tumor progression, without eliciting any unwanted effect. Thus, SA-decorated IBR nanocomplexes present a promising strategy for cancer immunotherapy. Ibrutinib (IBR), an irreversible Bruton’s tyrosine kinase (BTK) inhibitor, is expected to be a potent therapeutic modality, given that BTK is overexpressed in tumor-associated macrophages (TAMs) and participates in promoting tumor progression, angiogenesis, and immunosuppression. However, rapid clearance in vivo and low tumor accumulation have rendered effective uptake of IBR by TAMs challenge. Herein, we designed and synthesized a sialic acid (SA)–stearic acid conjugate modified on the surface of nanocomplexes to encapsulate IBR (SA/IBR/EPG) for targeted delivery of IBR to TAMs. The developed SA/IBR/EPG nanocomplexes exhibited high efficiency in targeting TAMs and inhibiting BTK activation, consequently inhibiting Th2 tumorigenic cytokine release, reducing angiogenesis, and suppressing tumor growth. These results implied that the SA/IBR/EPG nanocomplex could be a promising strategy for TAM-targeting immunotherapy with minimal systemic side effects." @default.
• W2945598045 created "2019-05-29" @default.
• W2945598045 creator A5003068382 @default.
• W2945598045 creator A5008806628 @default.
• W2945598045 creator A5009590736 @default.
• W2945598045 creator A5017353282 @default.
• W2945598045 creator A5030145539 @default.
• W2945598045 creator A5033610845 @default.
• W2945598045 creator A5035705128 @default.
• W2945598045 creator A5038305059 @default.
• W2945598045 creator A5051500470 @default.
• W2945598045 creator A5053022610 @default.
• W2945598045 creator A5067780588 @default.
• W2945598045 creator A5079702764 @default.
• W2945598045 creator A5082476673 @default.
• W2945598045 creator A5085660144 @default.
• W2945598045 creator A5088742385 @default.
• W2945598045 creator A5091194171 @default.
• W2945598045 date "2019-07-01" @default.
• W2945598045 modified "2023-09-30" @default.
• W2945598045 title "Targeted delivery of ibrutinib to tumor-associated macrophages by sialic acid-stearic acid conjugate modified nanocomplexes for cancer immunotherapy" @default.
• W2945598045 cites W1632321817 @default.
• W2945598045 cites W1831452211 @default.
• W2945598045 cites W1853090825 @default.
• W2945598045 cites W1909429521 @default.
• W2945598045 cites W1968918322 @default.
• W2945598045 cites W1969188151 @default.
• W2945598045 cites W1969740530 @default.
• W2945598045 cites W1975648747 @default.
• W2945598045 cites W1979514172 @default.
• W2945598045 cites W1981199702 @default.
• W2945598045 cites W1984803858 @default.
• W2945598045 cites W1991129425 @default.
• W2945598045 cites W1993345471 @default.
• W2945598045 cites W1996145004 @default.
• W2945598045 cites W1996213381 @default.
• W2945598045 cites W2003801328 @default.
• W2945598045 cites W2007063468 @default.
• W2945598045 cites W2007553857 @default.
• W2945598045 cites W2009763381 @default.
• W2945598045 cites W2011950935 @default.
• W2945598045 cites W2013909810 @default.
• W2945598045 cites W2018122406 @default.
• W2945598045 cites W2020744745 @default.
• W2945598045 cites W2027137358 @default.
• W2945598045 cites W2030094610 @default.
• W2945598045 cites W2033278321 @default.
• W2945598045 cites W2036304090 @default.
• W2945598045 cites W2040773741 @default.
• W2945598045 cites W2046304104 @default.
• W2945598045 cites W2051940153 @default.
• W2945598045 cites W2055348159 @default.
• W2945598045 cites W2071549499 @default.
• W2945598045 cites W2078643379 @default.
• W2945598045 cites W2083536542 @default.
• W2945598045 cites W2087572503 @default.
• W2945598045 cites W2088027633 @default.
• W2945598045 cites W2120377900 @default.
• W2945598045 cites W2125678285 @default.
• W2945598045 cites W2142530756 @default.
• W2945598045 cites W2154066874 @default.
• W2945598045 cites W2157200400 @default.
• W2945598045 cites W2160367702 @default.
• W2945598045 cites W2286673285 @default.
• W2945598045 cites W2293645537 @default.
• W2945598045 cites W2322282426 @default.
• W2945598045 cites W2340839484 @default.
• W2945598045 cites W2422924632 @default.
• W2945598045 cites W2528574508 @default.
• W2945598045 cites W2555820859 @default.
• W2945598045 cites W2582686270 @default.
• W2945598045 cites W2594374638 @default.
• W2945598045 cites W2601307136 @default.
• W2945598045 cites W2608151576 @default.
• W2945598045 cites W2624411770 @default.
• W2945598045 cites W2726179035 @default.
• W2945598045 cites W2765754868 @default.
• W2945598045 cites W2804749855 @default.
• W2945598045 cites W2805647212 @default.
• W2945598045 cites W2890796276 @default.
• W2945598045 cites W2909336678 @default.
• W2945598045 doi "https://doi.org/10.1016/j.actbio.2019.05.030" @default.
• W2945598045 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31108259" @default.
• W2945598045 hasPublicationYear "2019" @default.
• W2945598045 type Work @default.
• W2945598045 sameAs 2945598045 @default.
• W2945598045 citedByCount "60" @default.
• W2945598045 countsByYear W29455980452019 @default.
• W2945598045 countsByYear W29455980452020 @default.
• W2945598045 countsByYear W29455980452021 @default.
• W2945598045 countsByYear W29455980452022 @default.
• W2945598045 countsByYear W29455980452023 @default.
• W2945598045 crossrefType "journal-article" @default.
• W2945598045 hasAuthorship W2945598045A5003068382 @default.
• W2945598045 hasAuthorship W2945598045A5008806628 @default.
• W2945598045 hasAuthorship W2945598045A5009590736 @default.
• W2945598045 hasAuthorship W2945598045A5017353282 @default.
• W2945598045 hasAuthorship W2945598045A5030145539 @default.

• next